Abstract
January 1998 and they were treated with a standard MMF tinuation of MMF and prednisone because of intolerdose of 2 g/day. The control group was treated with prednis-ance to CsA. In four patients in the control group one combined with CsA (MMF− group; n=60) and they CsA was converted to AZA because of CsA nephrotoxreceived a graft between January 1992 and January 1997.
icity. Finally, in four patients in the control group A change in basic immunosuppressive therapy was MMF or AZA was added after a severe rejection recorded when this change lasted at least 1 month. Anti-(AZA, CsA and prednisone (n=3), or MMF, CsA rejection treatment consisted of intravenous administration and prednisone (n=1)). All these patients were of 1000 mg methylprednisolone on 3 consecutive days. If this included in the analysis. treatment failed, anti-T-lymphocyte therapy (antithymocyte globulin or monoclonal anti-T-cell antibodies) was instituted. No CMV prophylaxis was given in either group. CMV
CMV infection/disease
IgM/IgG antibodies and other laboratory parameters were assessed at time of transplantation and in case of clinical CMV seroconversion was detected in 18 of the 24 symptoms (i.e. fever, abdominal pain, etc.) of CMV infection. MMF-treated patients and in 38 of the 60 patients ( Figure 1 ). The maximum incidence of CMV infection fever for at least 2 days with one or more of the following: (assuming that CMV IgG was positive in the patients leukocytes <3.0×109/l, thrombocytes <100×109/l, alanine where it was not measured ) can be calculated as 79% aminotransferase (ALAT )>50 U/l (normal value: <35 U/l ) in the MMF+ group and 82% in the MMF− group. or histological evidence of tissue invasive disease. CMV CMV disease, however, was more frequent in the tissue invasive disease was defined as the histological finding MMF+ group than in the MMF− group (67 vs 30%, of intracytoplasmatic inclusion bodies surrounded by P<0.05) ( Figure 1 ). This means that in the MMF+ inflammatory cells.
group 84-89% of the primary CMV infections were symptomatic (=CMV disease) compared with 37-47% Statistics of the primary CMV infections in the MMF− group. The severity of the symptoms, frequency of tissueComparison of numerical data between the MMF+ group invasive disease and frequency or duration of treatment and the control group was carried out with the Wilcoxon's with ganciclovir in both groups of patients with CMV rank sum test. Proportions were compared with chi-square disease were similar ( Table 2 ). The first manifestation analysis. The analysis was done on an intention to treat basis of CMV disease appeared at the same interval after unless otherwise stated. A P-value <0.05 was considered transplantation in both groups (MMF+, median 49 statistically significant. days (range 33-116) vs MMF, median 51 days (range 29-259)). In 90% of the patients with CMV disease the first symptoms appeared within 3 months after
Results

RTx.
Restricting the above analysis to patients who did Clinical characteristics not receive antirejection treatment (MMF+, n=14; The mean age of the patients in the MMF+ group MMF−, n=31), or to the patients who remained on was 7 years higher than in the control group. Sex and the initial immunosuppressive regimen during the first number of retransplants were equally distributed 3 months after RTx (MMF+, n=20; MMF−, n= between the two groups ( Table 1) . There was no 51) gave the same results (data not shown). difference in the use of antirejection treatment in the first 3 months after RTx between both groups, although anti T cell therapy tended to be used less Discussion frequently in the MMF+ group (P=0.16). In twelve patients the immunosuppressive regimen was changed during the first 3 months after RTx (MMF+, n=4; In this retrospective study, the addition of MMF to CsA and prednisone did not appear to result in an MMF−, n=8). The median value of the interval between RTx and this change in therapy was 39 days increase of CMV infections in CMV seronegative patients who received a renal transplant of a CMV (range 14-63 days). Three patients in the MMF+ group discontinued MMF because of intolerance to seropositive donor (D+/R− combination). However, these primary CMV infections were nearly twice as this drug (bone-marrow suppression or gastrointestinal complaints). In one patient in the MMF+ group, the often symptomatic in patients treated with MMF compared with patients not treated with MMF. As a immunosuppressive therapy was reduced to the con- Underestimation of the frequency of CMV disease on the other hand seems unlikely, because our patients are instructed to contact us in case of fever or other clinical symptoms. Taking these factors into consideration thus strengthens the conclusion that CMV infection more often resulted in CMV disease in patients treated with MMF. The rate of antirejection treatment during the first 3 months after RTx did not differ between the groups. Our study design was not suited to detect differences in acute rejection incidence between both immunosuppressive treatment regimens, however, because patients with early graft loss were excluded from analysis. On the other hand, there was a tendency to In accordance with our data, a case control study reported no difference in the frequency of CMV infec- combinations, which is considered a high-risk populaGanciclovir treatment 1 course (%) 9 (56) 13 (72) tion for CMV infections. In addition, in contrast to 2 courses (%) 2 (13) 1 (6) common practice in many transplant centres, our patients did not receive anti-viral prophylaxis. These P-value not significant. factors may have contributed to a higher frequency of CMV infections and disease in our patients. It is unclear which factors determine whether CMV consequence, the large majority of the patients treated infections become symptomatic in immune compromwith MMF who became infected with CMV had a ised hosts. Both direct cytotoxicity of the virus due to symptomatic infection. The severity of these symptoa decreased immune surveillance of the host and immumatic CMV infections (=CMV disease) did not depend nopathogenicity of the immune response of the host on the use of MMF.
seem to contribute to symptomatology. In our study Because CMV serology was not repeated after trans-MMF was added to basic immunosuppressive therapy plantation in about 15% of the patients, the frequency with CsA and prednisone. The increase in symptomatic of CMV infections may be slightly underestimated in CMV infections in the MMF+ group might therefore both groups. Limiting the analysis to patients in whom be explained by an increase in net immune suppression. CMV serology was performed during follow-up
On the other hand, literature data and our experience resulted in an increase of the frequency of CMV infection to a similar rate in each group (about 80%). indicate that the use of MMF is not accompanied by an increase in other (i.e. bacterial or fungal ) infections. CMV infections was similar to that in patients not treated with MMF. MMF may cause some specific This argues against general attenuation of the immune response being the sole factor responsible for the change in the primary immune response to CMV infections. Further studies are warranted to elucidate increased incidence of CMV disease, and suggests that addition of MMF induces a specific change in the this change. primary immune response to CMV infections (and probably other herpes viruses as well ), which leads
